MSDI up 160% > This may be the catalyst that is sending this (LOI) merger, north: MSDI... Larazotide has received FDA Fast Track prepare for phase 3 clinical trials for larazotide in celiac disease later this year. Larazotide is the only drug which has successfully met its primary endpoint in an efficacy clinical trial for celiac disease. http://www.innovatebiopharma.com/PressReleases_6June2017.html
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.